Therapeutic package for the long term reduction of body fat stores insulin resistance hyperinsulinemia and hyperglycemia in vertebrates

A therapeutic package for dispensing to, or for use in dispensing to, a patient being treated for a metabolic condition selected from the group consisting of obesity, insulin resistance, hyperinsulinemia, and hyperglycemia comprising:

• one or more unit doses, each such unit dose comprising an amount of bromocriptine therein such that periodic administration of one or more of said unit doses is effective to treat said metabolic condition, and
• a finished pharmaceutical container therefor,
• said container containing said unit dose or doses,
• said container further containing or comprising labeling,
• said labeling directing the use of said package in the treatment of said metabolic condition in a dosage regimen under which the delivery of said bromocriptine is confined to the period during the day proximate to the time of day at which the serum prolactin concentration of a lean, insulin sensitive patient of the same sex is low, and further directing the use of said package in conjunction with the concomitant administration to said patient of one or more unit doses providing a therapeutically effective amount of a prolactin stimulator in a dosage regimen under which the delivery of said prolactin stimulator is confined to the period during the day after the time at which the serum prolactin concentration of a lean, insulin-sensitive patient of the same sex reaches its point of maximum depression and prior to the time of day when said prolactin concentration rises to a peak in lean, insulin-sensitive patients of the same sex.